HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma

2014

HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma

Keywords:

Correction
Source
Cite
Save
Machine Reading By IdeaReader

40

References

78

Citations